(Q36590472)

15 August 2017

1 reference

title

Treatment for renal cancer: are we beyond the cytokine era? (English)

1 reference

15 August 2017

Sara Ramsey

1

1 reference

15 August 2017

Michael Aitchison

series ordinal

2

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

15 August 2017

published in

Nature Reviews Urology

1 reference

15 August 2017

volume

3

1 reference

15 August 2017

issue

9

1 reference

15 August 2017

page(s)

478-484

1 reference

Pretreatment serum CRP and response to interleukin 2.

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0581

Interferon-alpha in malignant and viral diseases. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0581

7 January 2021

Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0581

7 January 2021

Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0581

7 January 2021

Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0581

7 January 2021

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0581

7 January 2021

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0581

7 January 2021

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0581

7 January 2021

Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0581

7 January 2021

The systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0581

7 January 2021

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0581

7 January 2021

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0581

7 January 2021

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0581

7 January 2021

Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0581

7 January 2021

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0581

7 January 2021

Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0581

7 January 2021

Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0581

7 January 2021

IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0581

7 January 2021

Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0581

7 January 2021

Practice and progress in kidney cancer: methodology for novel drug development

1 reference

https://api.crossref.org/works/10.1038%2FNCPURO0581

7 January 2021

Immunotherapy for advanced renal cell cancer

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD001425.PUB2

Identifiers

DOI

10.1038/NCPURO0581

1 reference

Dimensions Publication ID

15 August 2017

1026619091

0 references

1 reference